No Data
No Data
Express News | Oppenheimer Maintains Outperform on Cartesian Therapeutics, Maintains $50 Price Target
Cartesian Therapeutics Announces New Employment Inducement Grant
GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune
Express News | Cartesian Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Price Target $50
Cartesian Therapeutics Price Target Announced at $50.00/Share by Oppenheimer
Cartesian Therapeutics Price Target Announced at $50.00/Share by Oppenheimer
Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target
Cartesian Therapeutics (RNAC) has an average rating of buy and price targets ranging from $38 to $54, according to analysts polled by Capital IQ.
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Cuts Target Price to $40
Mizuho Securities analyst Uy Ear maintains $Cartesian Therapeutics(RNAC.US)$ with a buy rating, and adjusts the target price from $90 to $40.According to TipRanks data, the analyst has a success rate
No Data
T-24Century : looking good hehe
T-24Century : they add around 12m shares and the float is now at 280m from 55m before de added shares.
TrytosaveabitOP T-24Century: I think they have that wrong?
T-24Century : how can you calculate the math?
![laughing 😆](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f606.png)
the price should be maybe 38 -40?
TrytosaveabitOP T-24Century: That depends! Some calculate the market cap using shares in lockup and unregistered shares? Me I just use the price it’s trading at times the number of shares that are available for trading! That’s the difference between Float Market cap and Full Market Capitalization! Hope this help?
View more comments...